Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

Pharmaceutical giant Eli Lilly on Wednesday said it would seek Food and Drug Administration approval as soon as possible for an experimental drug to slow the ravages of Alzheimer’s disease after ...

Eli Lilly (LLY-4.22%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from ...

Experimental Eli Lilly Alzheimer’s drug donanemab is being readied for an FDA submission along the same regulatory path the agency used to approve Biogen’s Aduhelm. Though the Lilly drug met ...

A second drug that modestly slows the progression of Alzheimer’s disease could be approved by the end of this year, manufacturer Eli Lilly said Monday. In a statement, Lilly said it applied to ...